Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Google to Use Natural Gas to Power Massive Data Center in Texas - 2Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth
- 3Attacks on Iran's Bushehr nuclear plant and on Iraq border crossing
- 4Self-sacrificing ants highlight the unity of their colony, say researchers
- 5Figure out How to Function Successfully with Your Auto Collision Legal advisor for the Best Result
- Pick Your Favored pizza beating
- Polish law aimed at lowering petrol prices takes effect
- Knesset FADC extends emergency draft for 280,000 IDF reservists until January 1
- A definitive Manual for the 5 Off-road Bicycles Available
- Israel intensifies Lebanon attacks and hits areas not in Hezbollah's control
- The Significance of a Land Lawyer for Your Business
- Hot Electric Vehicles for 2023
- 3 astronauts settle into their new life in orbit | On the International Space Station this week Dec. 1-5, 2025
- Nitty gritty Manual for Picking Agreeable Tennis shoes
